Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Remdesivir

- PMLiVE

Researchers improve understanding of COVID-19 virus and future variants

The study aims to contribute to the design of future COVID-19 vaccines and drugs

- PMLiVE

NICE announces launch of refreshed support service for life sciences industry

NICE Advice will support pharmaceutical and healthtech companies and provide patients with access to quality treatments and care

- PMLiVE

International study reveals how to measure long COVID severity and impact

A set of 12 recommendations were established for scientific and clinical communities

- PMLiVE

Novavax’s XBB.1.5-adapted COVID-19 vaccine receives EC approval

Individuals aged 12 years and older will be eligible to receive the updated COVID-19 vaccine

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

University of Oxford launches new trial to enhance flu and COVID-19 vaccines

Results from the study are expected to help increase the protection of future vaccines

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

- PMLiVE

AstraZeneca studies highlight burden of COVID-19 for immunocompromised

The risk of hospitalisation due to COVID-19 was 14 times greater for IC individuals

- PMLiVE

Differences in immune responses could optimise future COVID-19 vaccines

Vulnerability to different mutations was linked to previous infections and vaccination

- PMLiVE

Moderna’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

New vaccine technology could help fight future viruses and variants

The antigen technology could enhance vaccine protection against potential threats

- PMLiVE

Novavax’s updated COVID-19 vaccine approved by FDA for emergency use

Individuals aged 12 years and older will be eligible to receive the company's updated vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links